Inhibition of platelet aggregation of a mutant proinsulin molecule engineered by introduction of a native Arg-Gly-Asp sequence

Citation
Zh. Yang et al., Inhibition of platelet aggregation of a mutant proinsulin molecule engineered by introduction of a native Arg-Gly-Asp sequence, APPL BIOC B, 90(1), 2001, pp. 1-10
Citations number
17
Categorie Soggetti
Biotecnology & Applied Microbiology","Biochemistry & Biophysics
Journal title
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
ISSN journal
02732289 → ACNP
Volume
90
Issue
1
Year of publication
2001
Pages
1 - 10
Database
ISI
SICI code
0273-2289(200101)90:1<1:IOPAOA>2.0.ZU;2-P
Abstract
A 13 amino acid sequence, CRVARGDWNDNYC, originated from disintegrin eristo statin, was introduced into an inactive human proinsulin molecule between t he B29 and A2 sites to replace proinsulin C-peptide by molecular cloning te chniques. The constructed Arg-Gly-Asp (RGD)-proinsulin-7 gene was cloned in to a temperature-inducible vector pBV220 and expressed in Escherichia coli. The expressed RGD-proinsulin was refolded and purified by Sephadex G50 and DEAE-Sephadex A25 separations. The chemical identity was confirmed by both amino acid composition and mass spectrometry analyses. This RGD-proinsulin showed an inhibitory activity of adenosine 5'-diphosphate-induced human pl atelet aggregation with an IC50 value of 200 nM. Its insulin receptor bindi ng activity remained as low as 0.03% with native insulin as a control, and its insulin immune activity retained 27.6% compared with proinsulin.